PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.06%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.76%. Joel Greenblatt would investigate if growth quality matches quantity.
4.31%
Cost growth near Medical - Pharmaceuticals median of 4.31%. Charlie Munger would verify if industry cost structure is attractive.
3.06%
Gross profit growth 1.25-1.5x Medical - Pharmaceuticals median of 2.17%. Mohnish Pabrai would examine sustainability.
-0.96%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
40.30%
Other expenses change of 40.30% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
6.04%
Operating expenses growth near Medical - Pharmaceuticals median of 6.63%. Charlie Munger would verify industry norms.
4.59%
Total costs growth 50-90% of Medical - Pharmaceuticals median of 6.73%. Mohnish Pabrai would examine discipline.
-6.67%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
6.44%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.08%. Jim Chanos would check for overinvestment.
-5.37%
EBITDA decline while Medical - Pharmaceuticals median is -5.65%. Seth Klarman would investigate causes.
-9.06%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-7.53%
Operating income decline while Medical - Pharmaceuticals median is -0.37%. Seth Klarman would investigate causes.
-11.13%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-105.16%
Other expenses reduction while Medical - Pharmaceuticals median is -15.93%. Seth Klarman would investigate advantages.
-44.80%
Pre-tax income decline while Medical - Pharmaceuticals median is -14.49%. Seth Klarman would investigate causes.
-46.95%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-66.92%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-34.48%
Net income decline while Medical - Pharmaceuticals median is -13.20%. Seth Klarman would investigate causes.
-37.04%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-34.48%
EPS decline while Medical - Pharmaceuticals median is -9.72%. Seth Klarman would investigate causes.
-34.48%
Diluted EPS decline while Medical - Pharmaceuticals median is -9.72%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.